21健讯Daily｜北京推出32条措施支持创新医药高质量发展；恒瑞医药一款小分子新药授权默克

Policy Developments - Beijing's Medical Insurance Bureau and nine other departments issued measures to support high-quality development of innovative pharmaceuticals by 2025, including accelerating the use of self-developed in vitro diagnostic reagents and expanding the import categories for rare disease medications [2] - The document outlines 32 new initiatives aimed at enhancing clinical trial efficiency, improving review and approval processes, and promoting the clinical use of innovative medicines and medical devices [2] Drug and Device Approval - Novartis' application for the new indication of inclisiran, a long-acting siRNA therapy for lowering LDL-C, has been accepted by China's National Medical Products Administration [5] Capital Market - Hangzhou Lingmou Medical Technology Co., Ltd. completed several million RMB in Series A financing, led by Jiuhe Venture Capital [7] - Chengdu Saiyun Biotechnology Co., Ltd. announced the completion of several million RMB in angel+ financing, with funds aimed at accelerating the development of its self-researched pipeline [8] Industry Events - Tianjing Bio announced a clinical research collaboration with Biogen for the development of the monoclonal antibody Fizezotuzumab for treating IgA nephropathy and primary membranous nephropathy in China [10] - Merck KGaA acquired exclusive commercialization rights for Hengrui Medicine's oral GnRH receptor antagonist SHR7280 in mainland China, with an upfront payment of €15 million [12] Financial Reports - China National Pharmaceutical Group reported a net profit of approximately 642 million RMB for 2024, a decrease of 59.83% year-on-year, with total revenue of about 74.378 billion RMB, down 1.46% [14] - Health元 reported a net profit of 1.387 billion RMB for 2024, a decline of approximately 3.9% year-on-year, with total revenue of 15.619 billion RMB, down about 6.17% [15]